A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
168actual
Sites
40
Countries
Australia, Canada, Israel +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-07-13 | actual | When the study began enrolling |
| Primary completion | 2025-09-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-12 | actual | The whole study's end, after follow-up |
| First posted | 2018-07-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumors
Interventions
- Drug: ABBV-155
- Drug: Paclitaxel
- Drug: Docetaxel
Primary outcomes
what the primary-completion date above is the date OFMTD and/or RPTD of ABBV-155
measured Up to approximately 21 days after initial dose of study drug
Overall Response Rate (ORR)
measured Up to approximately 2 to 6 months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed